Rationale Bulimia nervosa (BN) is highly comorbid with substance abuse and shares common phenotypic and genetic predispositions with drug addiction. Although treatments for the two disorders are similar, controversy remains about whether BN should be classified as addiction. Objectives Here, we review the animal and human literature with the goal of assessing whether BN and drug addiction share a common neurobiology. Results Similar neurobiological features are present following administration of drugs and bingeing on palatable food, especially sugar. Specifically, both disorders involve increases in extracellular dopamine (DA), D1 binding, D3 messenger RNA (mRNA), and ΔFosB in the nucleus accumbens (NAc). Animal models of BN reveal increases in ventral tegmental area (VTA) DA and enzymes involved in DA synthesis that resemble changes observed after exposure to addictive drugs. Additionally, alterations in the expression of glutamate receptors and prefrontal cortex activity present in human BN or following sugar bingeing in animals are comparable to the effects of addictive drugs. The two disorders differ in regards to alterations in NAc D2 binding, VTA DAT mRNA expression, and the efficacy of drugs targeting glutamate to treat these disorders. Conclusions Although additional empirical studies are necessary, the synthesis of the two bodies of research presented here suggests that BN shares many neurobiological features with drug addiction. While few Food and Drug Administrationapproved options currently exist for the treatment of drug addiction, pharmacotherapies developed in the future, which target the glutamate, DA, and opioid systems, may be beneficial for the treatment of both BN and drug addiction.
Introduction
Bulimia nervosa (BN) is an eating disorder characterized by recurrent binge eating episodes coupled with compensatory behaviors to avoid weight gain, a lack of control over eating, fear of gaining weight, and distorted body image. The Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition, defines a binge eating episode as the ingestion of a larger amount of food than most individuals would eat in a similar situation within 2 h (American Psychiatric Association 2013). Binges can include a variety of foods, but typically include sweet, high-calorie foods (Broft et al. 2011; Fitzgibbon and Blackman 2000) . The DSM-IV TR classifies two types of BN: (1) the purging type, which is characterized by regular engagement in self-induced vomiting or the misuse of laxatives, enemas, or diuretics, and (2) the nonpurging type, which includes other inappropriate compensatory behaviors, such as fasting or excessive exercise (American Psychiatric Association 2000) . However, since most BN individuals engage in both "purging" and "nonpurging" compensatory behaviors, the DSM-5 has combined these two types of BN and refers to them collectively as purge behaviors (American Psychiatric Association 2013). BN affects between 1 and 3 % of the population across American, European, and Australian cultures (Smink et al. 2012) and is highly comorbid with substance use disorders (American Psychiatric Association 2013; Conason and Sher 2006; Nøkleby 2012) . Relative to the general public, individuals with eating disorders are at a fivefold increased risk of abusing alcohol or illicit drugs (The National Center on Addiction and Substance Abuse 2003) .
Given the high rates of comorbidity and the phenotypic and genetic similarities between eating and substance use disorders, eating disorders have been proposed to be a form of addiction (Brisman and Siegel 1984; Carbaugh and Sias 2010; Conason and Sher 2006) . Specific to BN, behavioral characteristics associated with repeated binge eating episodes, preoccupation with food and weight, difficulty abstaining from binge eating and compensatory behaviors, and eating in secrecy are analogous to characteristics of substance dependence that include repeated substance consumption, obsession with the substance, unsuccessful efforts to reduce use, and withdrawal from social activities in order to use the substance in private or with substance-using friends (American Psychiatric Association 2013). Genetically, the single nucleotide polymorphism Taq1A in the dopamine DRD2/ANKK1 gene (Berggren et al. 2006; Connor et al. 2008; Nisoli et al. 2007 ) and polymorphisms in the serotonin system (Di Bella et al. 2000; Gervasini et al. 2012; McHugh et al. 2010) similarly increase risk for acquiring both BN and drug addiction, further corroborating the idea that BN is a type of addiction.
Despite symptom and genetic commonalities among BN and drug addiction, and the fact that addiction models are used as a basis for treatment of BN (Trotzky 2002; Wilson 1995) , there remains controversy about whether or not BN is a form of addiction. This problem results, at least in part, from difficulties associated with modeling BN in laboratory animals. Although there is no perfect animal model of BN, several animal paradigms that capture characteristics of BN have been created (for detailed review of these models, see Avena and Bocarsly 2012) . These animal models have allowed for great advances in the study of BN, but the number of studies assessing the neurobiology of BN is fewer than those investigating substance abuse.
Binge eating is a critical diagnostic component of BN (American Psychiatric Association 2013) and, as discussed above, typically involves overconsumption of sweet, high calorie foods (Broft et al. 2011; Fitzgibbon and Blackman 2000) . Another essential component of BN is the use of inappropriate compensatory behaviors, such as fasting and purging (American Psychiatric Association 2013). As such, here we focus primarily on animal models that pair bingeing of sweet or high fat foods with experimenter-or self-induced restriction or purging. To date, little is known about how the neurobiology of BN maps on to current addiction models. Thus, the present review synthesizes results of animal and human studies of BN and drug addiction in order to examine whether BN shares neurobiological features with drug addiction.
Animal models of BN
Several animal paradigms that recapitulate characteristics of BN are used to study the neurobiology of BN. Given that the DSM-5 is relatively new, animal models typically mimic traits associated with one of the two types of BN described in the DSM-IV TR: nonpurging and purging BN. Thus, for the remainder of this paper, we will utilize the distinction between nonpurging and purging BN as outlined by the DSM-IV TR and described above.
Modeling nonpurging BN
The "food restriction/deprivation" model uses rats to recapitulate the nonpurging type of BN by imposing periods of food restriction or deprivation and periods of free access to chow or palatable foods (e.g., (Hagan and Moss 1991; Hagan and Moss 1997) ). After three cycles of food deprivation to 75 % of normal body weight followed by recovery to normal weight, rats display binge-like eating during the first hour of ad lib feeding of rat chow (Hagan and Moss 1991) . Similarly, rats subjected to 12 weeks of 4-day food restriction periods followed by 2-4-day periods of free access to chow or palatable foods experience hyperphagia during free access periods (Hagan and Moss 1997) . Notably, these rats exhibit long-term aberrant feeding patterns and continue to display binge-eating behaviors even after returning to a normal feeding schedule and body weight, particularly when presented with palatable food (Hagan and Moss 1997) .
In the "sugar addiction" model, rats are given intermittent access to a sugar solution: 12-16 h of food deprivation followed by 8-12 h of access to 10 % sucrose or 25 % glucose plus chow and water daily (e.g., Avena et al. 2006a Avena et al. , 2008a Colantuoni et al. 2002) . Compared to control rats, rats given intermittent access to sucrose increase sucrose intake and display binge-like behaviors, which is defined by the amount of sucrose consumed during the first hour of each access period (Avena et al. 2006a (Avena et al. , 2008a Colantuoni et al. 2002) . Notably, rats given intermittent access to a sucrose solution voluntarily eat significantly less regular chow than rats given intermittent or ad libitum access to chow (Avena et al. 2006a (Avena et al. ,2008a . This hypophagia is similar to eating patterns of BN individuals who tend to restrict food intake preceding and following binges (American Psychiatric Association 2013). Rats given intermittent access to sugar (but not regular chow) also display physical signs of withdrawal (e.g., teeth chattering, head shaking) after 24-36 h of deprivation. This model allows for the assessment of neurobiological features during binge eating and subsequent restriction, which accurately models key characteristics of nonpurging BN.
Unlike the models described above, the "limited access" model does not expose rats to food restriction or deprivation. Rather, rats are given ad libitum access to standard chow and water, as well as intermittent access to a palatable food composed of fat, sugar, or a fat/sugar combination for 1-2 h (e.g., Corwin and Wojnicki 2006; Wong et al. 2009 ). Rats given intermittent access to 100 % vegetable shortening binge on fat and voluntarily decrease regular chow consumption (Corwin and Wojnicki 2006) . This decrease in standard chow consumption is similar to rats given intermittent access to a 10 % sucrose solution (e.g., Avena et al. 2008a ) and hypophagia seen in BN individuals (American Psychiatric Association 2013). Thus, the "limited access" model recapitulates eating patterns of nonpurging BN-individuals by capturing self-imposed restriction coupled with bingeing.
Taken together, the "food restriction/deprivation" model, the "sugar addiction" model, and the "limited access" model all induce binge eating. Furthermore, they are characterized by experimenter-or self-imposed restriction. As detailed above, bingeing and restriction are two key features of nonpurging BN. Thus, by interchanging periods of binge eating and restriction of chow and/or palatable food, these models serve as satisfactory animal models of nonpurging BN.
Modeling purging BN
Creating an animal model of the purging type of BN has been difficult because rats lack the esophageal muscular anatomy to vomit. Thus, in order to capture both bingeing and purging behaviors in one animal model, researchers have combined the sham-feeding rat model with binge eating (e.g., Avena et al. 2006b ). In the sham-feeding rat model, a gastric fistula is inserted into the rat's stomach or esophagus, resulting in minimal contact between food and the animal's gastric and intestinal mucosa. Because the gastric fistula causes ingested liquid to drain from the rat's stomach, caloric absorption is limited (Casper et al. 2008) . By cycling sham-fed rats through a 12-h food restriction period followed by 12 h of free access to food, rats binge on sweet foods and purge via the gastric fistula (Avena et al. 2006b ). This procedure has been recently validated among BN individuals (see (Klein and Smith 2013) ). Specifically, BN women who are modified sham-fed by sipping and spitting on liquid solutions engage in hyperphagia, whereas normal controls and women with anorexia nervosa do not. Thus, although animal models cannot fully capture the complexity of human eating disorders (Avena and Bocarsly 2012) , the sham-feeding rat model coupled with binge eating accurately captures purging BN.
Criteria for inclusion in the present review
The animal models described above recapitulate key characteristics of BN. Mimicking nonpurging BN, the "food restriction/deprivation," "sugar addiction," and "limited access" models couple bingeing with experimenter-or selfimposed restriction. Importantly, these are two key characteristics of nonpurging BN (American Psychiatric Association 2000) . Capturing the two main components of purging BN (American Psychiatric Association 2000), the sham-feeding/bingeing model recapitulates bingeing coupled with purging. There are other models of BN, such as the restriction-stress model that couples food restriction with stress (e.g., Hagan et al. 2002; Inoue et al. 1998 ). However, these models have not been used to assess neurobiological changes addressed in this manuscript, and thus, they will not be discussed.
The present review includes animal models described above. Since restriction and bingeing are the main components of BN (American Psychiatric Association 2013), also included here are findings from studies that involve either fasting or bingeing in laboratory animals. We compare results from such studies to those obtained using various models of drug addiction, which each capture essential components of human addiction: conditioned place preference, operant drug self-administration, oral consumption of alcohol, and the reinstatement of drug-seeking following extinction of the drugseeking response. Importantly, unlike recent reviews that compare the neurobiological underpinnings of addiction to that of binge eating in animals that leads to obesity (e.g., DiLeone et al. 2012; Volkow et al. 2013) , findings from studies using animal models of obesity are not included here because BN individuals are not typically overweight (American Psychiatric Association 2013).
The neurobiology underlying the acquisition of addiction
Addictive drugs such as cocaine, amphetamines, opiates, alcohol, and nicotine all directly or indirectly stimulate DA neurons in the ventral tegmental area (VTA), resulting in the release of DA into the nucleus accumbens (NAc) and prefrontal cortex (PFC) (for review, see Bromberg-Martin et al. 2010) . While the precise role of this DA release in directing behavior has been debated over the course of the past three decades, it is clear that DA release in these regions is an essential mediator of the acquisition of drug seeking (for review, see Wise 2004) . DA release is necessary to encode environmental cues and behavioral responses associated with obtaining rewards and enables the use of learned information to execute drug-seeking behavior (for review, see Schultz 2004; Wise 2004) .
DA cell bodies are found in the VTA and the substantia nigra (SN). The VTA sends projections to the NAc via the mesolimbic DA pathway and to the PFC via the mesocortical pathway. The SN projects to both the ventral and dorsal striatum. Postsynaptic DA receptors are grouped into D1-like receptors, which include the D1 and D5 subtypes, and D2-like receptors, which include D2, D3, and D4 receptors. D1-like receptors are Gs-coupled and are preferentially expressed on the postsynaptic membrane, while D2-like receptors are Gi-coupled and are expressed both pre-and postsynaptically. The consequences of binding at these receptor types are varied depending on the site of expression and brain region (for details, see review by El-Ghundi et al. 2007 ). As discussed below, both D1 and D2 receptors are implicated in addiction, as is the DA transporter (DAT), which is responsible for the removal of DA from the extracellular space. In this section, we review results obtained from animal studies of BN to ascertain if the effects of BN on the mesolimbic DA system are comparable to those of addictive drugs.
Nucleus accumbens dopamine
Stimulation of DA neurons in the VTA causes DA to be released in the NAc and regulates motivated behavior and the acquisition of drug addiction. Ethanol, nicotine, opiates, amphetamine, and cocaine increase DA levels in the NAc, but drugs not abused by humans do not alter DA levels in this area (Di Chiara and Imperato 1988) . Furthermore, whereas DA release is sustained following repeated drug administration, the effect of food on DA release abates over time unless food availability is novel or inconsistent (Ljungberg et al. 1992; Mirenowicz and Schultz 1994) . Here, we discuss data derived from animal models of purging and nonpurging BN, which indicate that the NAc DA response to palatable food differs from that to regular chow.
In their study of sucrose sham-fed-sucrose-bingeing rats, Avena et al. (2006b) examined NAc DA release in response to sucrose. Rats in the sham-fed groups whose gastric fistulas were open during the first hour of food access displayed sucrose-bingeing behavior and consumed significantly more sucrose during the first hour of access on all testing days (days 1, 2, and 21) relative to real-fed rats whose gastric fistulas remained closed. In vivo microdialysis revealed that NAc extracellular DA significantly increased for both sham-fed and real-fed rats in response to tasting sucrose on all testing days. Importantly, although sucrose ingested during the first binge was immediately drained from sham-fed rats' stomachs, the DA response in the NAc continued to be observed on day 21. Similar results have been found using variations of the "sugar addiction" model. Exposing rats to a 12-h food restriction period followed by a period of free access to sugar results in daily sugar bingeing and continued DA release in the NAc shell on days 1, 2, and 21 of sugar access (Rada et al. 2005) . In contrast, control rats with ad libitum access to chow or sugar or ad libitum access to chow with access to sucrose for only 1 h on 2 days do not binge on sugar, nor do they exhibit maintained DA release in the NAc shell. In another study, rats were deprived of food for 16 h followed by access to chow for 8 h with a 10 % sucrose solution available for the first 2 h for 21 days, resulting in sugar bingeing and significant increases in extracellular NAc DA on day 21 (Avena et al. 2008b ). On day 28, after 7 days of being reduced to 85 % of their original body weight, rats that drank sucrose showed an increase in NAc DA that was significantly higher than NAc DA release that resulted from drinking sucrose at normal body weight on day 21 (Avena et al. 2008b ). In another study, cycling rats through 28 days of the "sugar addiction" protocol followed by 36 h of fasting resulted in significantly lower NAc shell DA relative to rats given intermittent or ad libitum access to chow (Avena et al. 2008a) .
Taken together, while restriction or sham-feeding coupled with sucrose-bingeing results in extracellular NAc DA increases, which do not habituate over time (e.g., Avena et al. 2008b; Avena et al. 2006b; Colantuoni et al. 2001; Rada et al. 2005) , DA levels decrease in the NAc shell during fasting periods (e.g., Avena et al. 2008a ). When 2-h access to sucrose is regained after fasting periods, extracellular NAc DA levels exceed what is observed in control animals given access to sucrose, which is indicative of a sensitized DA response (e.g., Avena et al. 2008b) . Similarly, rats exposed to cocaine, morphine, nicotine, tetrahydrocannabinol, and heroin display increased extracellular NAc DA (e.g., Di Chiara and Imperato 1988; Gaddnas et al. 2002; Pothos et al. 1991; Tanda et al. 1997) , whereas withdrawal from these substances decreases NAc DA (Acquas and Di Chiara 1992; Barak et al. 2011; Gaddnas et al. 2002; Mateo et al. 2005; Natividad et al. 2010; Pothos et al. 1991; Rada et al. 2001; Weiss et al. 1992; Zhang et al. 2012) . Likewise, the firing rate of VTA DA neurons decreases upon morphine (Diana et al. 1999 ) and cannabinoid (Diana et al. 1998) withdrawal. Similar to DA activity in response to sucrose after a period of restriction (Avena et al. 2008b ), NAc DA concentrations increase when rats are reexposed to nicotine after a 1-or 10-day period of withdrawal from 4 or 12 weeks of oral nicotine self-administration (Zhang et al. 2012) . The firing rate of VTA DA neurons significantly increase in response to morphine (Diana et al. 1999 ) and cannabinoid (Diana et al. 1998 ) administration after withdrawal. However, a cocaine challenge injection after 1 or 7 days of withdrawal from extended access selfadministration fails to increase NAc DA, indicating the development of tolerance and not sensitization (Mateo et al. 2005) . Following short-access intravenous nicotine selfadministration, a nicotine challenge after 24 h of withdrawal produces NAc DA elevations that are lower than those observed in drug-naive rats, also indicating the development of tolerance (Rahman et al. 2004) . While extended access methamphetamine self-administration (Le Cozannet et al. 2013) produces results akin to Rahman et al. (2004) , methamphetamine challenge injections following both noncontingent and short access to methamphetamine self-administration result in sensitized DA release relative to naive controls (Lominac et al. 2012) .
In sum, while the reintroduction of palatable food after a period of deprivation results in sensitized DA release, the same effect is only observed following withdrawal from selfadministered oral nicotine, self-administered short-access methamphetamine, and noncontingent administration of cannabinoids, morphine, and methamphetamine. DAT activity decreases after a period of fasting (Patterson et al. 1998) , which may contribute to elevated DA observed in this brain region during refeeding. A similar effect is seen during withdrawal from experimenter-administered methamphetamine (German et al. 2012 ).
Nucleus accumbens dopamine receptor expression Rats exposed to a repeated restriction-refeeding cycle with access to both glucose and chow for 31 days progressively increase glucose intake, but not chow intake (Colantuoni et al. 2001 ). Twelve to 15 h after bingeing, D1 receptor binding in the NAc shell and core is significantly higher in foodrestricted, glucose-bingeing rats relative to controls. Within 1.5-2.5 h after a sucrose binge, rats that are food restricted and given limited access to sucrose and chow for 7 days exhibit significantly lower D2 binding in the NAc relative to rats given limited access to chow alone (Bello et al. 2002) . Relative to control animals given only chow, rats with intermittent access to sucrose for 21 days become sucrose dependent and exhibit decreased D2 messenger RNA (mRNA) and increased D3 mRNA in the NAc 1 h after gaining access to sucrose and chow (Spangler et al. 2004) .
Similar increases in NAc D1 receptor binding and/or mRNA levels have been found following repeated noncontingent administration of cocaine (Unterwald et al. 2001) , nicotine (Bahk et al. 2002) , and amphetamine (Young et al. 2011 ). However, Le Foll et al. (Le Foll et al. 2003) found only increased D3 binding and mRNA but no change in D1 following noncontingent nicotine. Similarly, Metaxas et al. (2010) found no change in D1 expression following nicotine self-administration. Both continuous and intermittent selfadministration of alcohol (Sari et al. 2006 ) and extended access to cocaine self-administration (Ben-Shahar et al. 2007 ) increase D1 mRNA as well as its surface expression (Conrad et al. 2010) .
Increased D1 expression likely leads to a sensitized response to DA. The release of DA and subsequent stimulation of D1 receptors in the NAc occurring upon administration of addictive drugs produces a signaling cascade that includes an increase in expression of transcription factors such as ΔFosB (for review, see Nestler et al. 2001) . Preventing ΔFosB transcriptional activity reduces the rewarding effects of drugs (Zachariou et al. 2006) , and overexpression enhances drug reward (Colby et al. 2003; Kelz et al. 1999; Zachariou et al. 2006) . Food restriction also increases ΔFosB levels in the NAc of rats (Stamp et al. 2008; Vialou et al. 2011) , which increases the motivation to obtain highly palatable food rewards, as evidenced by the finding that viral vector-mediated overexpression of ΔFosB increases consumption of palatable food (Vialou et al. 2011) . Thus, it is likely that BN increases ΔFosB levels in the NAc in a manner similar to addictive drugs, thereby increasing the rewarding value of bingeing.
Bingeing also results in decreased D2 binding in the NAc (e.g., (Bello et al. 2002; Colantuoni et al. 2001; Spangler et al. 2004) ). Notably, Taq1A, a common genetic polymorphism found among BN and drug-addicted individuals (Berggren et al. 2006; Connor et al. 2008; Nisoli et al. 2007) , is related to reduced D2 receptor density (Neville et al. 2004) . Although cocaine decreases D2 expression in the NAc (Conrad et al. 2010) , repeated experimenter-administered nicotine (Bahk et al. 2002) , experimenter-administered amphetamine (Mukda et al. 2009 ), and self-administered alcohol (Sari et al. 2006 ) increase D2 expression among rats. In light of the work with human drug addicts showing reductions in D2 binding (Volkow et al. 2001; Volkow et al. 1993) , it is interesting that the same phenomenon is not observed following nicotine, amphetamine, or alcohol exposure in animals. However, the reduction in D2 binding seen in humans may precede drug exposure, and thus, lower D2 levels would not necessarily be observed following exposure in animals. A reduction in D2 expression would likely produce increased DA efflux that could drive bingeing or drug seeking.
In summary, sucrose bingeing in animal models of BN results in sustained elevation of NAc DA, increased D1 receptor binding and D3 mRNA, and decreased D2 receptor binding and mRNA in the NAc. While the D1 and D3 changes parallel those produced by addictive drugs (with the possible exception of nicotine for D1 changes), D2 reductions are not observed in many animal studies of drug addiction. It is possible that while D2 reductions present in humans serve to drive drug consumption, these reductions precede drug use and are not caused by it. Dopamine in the ventral tegmental area Dopaminergic cell bodies in the VTA project to the PFC, hippocampus, amygdale, and NAc. Somatodendritic release of DA also occurs in the VTA upon cell firing (Beckstead et al. 2004) and has a significant impact on the activity of dopaminergic VTA neurons. This form of DA release activates local inhibitory D2 autoreceptors (Cragg and Greenfield 1997) , thus inhibiting DA cell firing in the VTA (Bernardini et al. 1991; Wang 1981; White and Wang 1984) and DA release in the PFC and NAc terminal fields (Kalivas and Duffy 1991; Zhang et al. 1994) . Therefore, somatodendritic release of DA in the VTA plays a pivotal role in the regulation of DA transmission along the mesocorticolimbic projections.
In vivo microdialysis has been used to examine concentrations of VTA DA during refeeding. Rats were deprived of food and water for 36 h prior to a period of refeeding during which microdialysis was performed (Yoshida et al. 1992) . A significant increase in VTA DA concentrations was observed during refeeding and drinking relative to baseline. VTA DA levels were sustained for 20-40 min after the end of the feeding and drinking sessions. Similarly, an IP injection of ethanol results in heightened extracellular VTA DA within 20 min, which then peaks 40 min after the injection and then declines to baseline (Kohl et al. 1998) . Likewise, intravenous (Bradberry and Roth 1989) and IP (Reith et al. 1997; Zhang et al. 2001 ) cocaine administration and acute IP injections of methamphetamine (Zhang et al. 2001 ) increase extracellular DA in the VTA. While results of the study of Yoshida et al. (1992) study suggest an important role of VTA DA in feeding behaviors, rats in the study were only cycled through one period of food restriction and refeeding, and binge-eating behaviors were not assessed. Furthermore, there was no control group in the study, so it is unknown if the same effect would be seen among rats not exposed to the deprivationrefeeding paradigm. As such, conducting the same experiment using an animal model of BN is necessary.
Transmission along the mesolimbic projection is also modulated by DAT mRNA levels. DAT mRNA is synthesized in the VTA and regulates DA reuptake within the VTA. It is also transported to the NAc to regulate synaptic reuptake of DA. To date, only one study has assessed DAT adaptations in the VTA utilizing an animal model of BN (Bello et al. 2003) . In the study, rats were either food-restricted or given ad libitum access to sucrose or standard chow, followed by a first meal of either sucrose or standard chow. Food-restricted rats given scheduled-access to sucrose consumed significantly more chow than any other group of rats. However, in contrast to previous research (e.g., Avena et al. 2006a Avena et al. , 2008a Colantuoni et al. 2002; Corwin and Wojnicki 2006; Hagan and Moss 1997) ), group differences in sucrose intake were not found (Bello et al. 2003) . Conflicting results may be due to the fact that Bello and colleagues cycled rats through the protocol only once and presented rats with only 20-min access to sucrose. However, group differences in sucrose intake arise when rats are cycled through deprivation and access several times and are granted access to sucrose for 1-12 h (e.g., Avena et al. 2006a Avena et al. , 2008a Colantuoni et al. 2002; Corwin and Wojnicki 2006; Hagan and Moss 1997) . Nonetheless, rats were found to increase their sucrose intake by threefold over the course of 7 days (Bello et al. 2003) , indicating binge-like behaviors. Relative to controls and rats given free-or scheduled-access to chow, rats given restricted access to scheduled sucrose displayed significantly higher DAT binding and mRNA levels in the VTA and DAT binding in the NAc (Bello et al. 2003 ). As discussed above, NAc DA increases upon presentation of palatable food, and the upregulation in DAT expression in the NAc may occur as an attempt to compensate for this increase. This suggests that nonpurging BN coupled with sucrosebingeing produces effects on VTA DA that differ from those produced by the ingestion of nonpalatable foods. Repeated exposure to amphetamine (Lu and Wolf 1997; Shilling et al. 1997 ) and nicotine (Li et al. 2004 ) increases VTA DAT mRNA. In contrast, noncontingent cocaine decreases (Cerruti et al. 1994) , while both limited and extended access to cocaine self-administration have no effect on (Ben-Shahar et al. 2006), DAT mRNA expression in the VTA.
Research using animal models of food restriction suggest that dopaminergic VTA efferents may regulate this key characteristic of nonpurging BN. Relative to control rats with free access to food, rats undergoing chronic food restriction display increased VTA expression of two enzymes involved in DA synthesis: tyrosine hydroxylase (TH) and aromatic Lamino acid decarboxylase (AAAD) (Lindblom et al. 2006 ). Thus, a period of fasting may prepare VTA DA neurons to release greater amounts of DA in the NAc upon presentation of palatable food. Chronic food restriction results in a significant increase in the expression of DAT in the VTA (Lindblom et al. 2006) . However, it is important to note that food restriction is only one characteristic of nonpurging BN. Thus, future research should examine how bingeing coupled with food restriction or purging influences VTA TH, AAAD, and DAT levels. Chronic cocaine and morphine administration significantly increase VTA TH immunoreactivity (Beitner-Johnson and Nestler 1991), but methamphetamine administration does not significantly alter TH mRNA levels in the VTA (Shishido et al. 1997) .
In sum, animal models that mimic nonpurging BN and other key components of BN, such as food restriction, have been used to find increased DAT mRNA, elevated expression of enzymes associated with DA synthesis (TH and AAAD), and increased DA concentrations in the VTA. These results are comparable to neuroadaptations found following repeated amphetamine, morphine, and nicotine exposure, but conflict with those produced by noncontingent and self-administered cocaine as well as methamphetamine administration. Taken together, preliminary findings reviewed in this section indicate that VTA dopaminergic alterations present in animal models of BN are similar to those present following exposure to certain addictive drugs.
The effects of dopamine antagonists on binge eating and drug seeking
Because DA release occurs in the NAc during bingeing, a number of studies have examined the ability of systemic administration of D1 and D2 receptor antagonists to modulate this behavior. Using the limited-access protocol with fat/ sucrose mixtures, Wong et al. (2009) found that the D2 antagonist raclopride exerts dose-dependent reductions in the binge consumption of palatable foods with specific concentrations of sucrose. In their study, rats were permitted access to a mixture of 100 % shortening with either 3.2, 10, or 32 % sucrose (w/w) for 1 h, with either daily or intermittent (MWF) access. Only rats given intermittent access to palatable food containing either 3.2 or 10 % sucrose met the criteria for bingeing. In these animals, the 0.1 mg/kg (IP) dose of raclopride increased bingeing, while the 0.3 mg/kg (IP) dose decreased consumption of the palatable food in rats consuming 3.2 % sucrose. Raclopride did not have an effect on intake among rats given daily-or intermittent-access to a high (32 %) sucrose concentration fat/sucrose mixture at any dose, nor did it affect consumption in rats given daily access. In a similar study by the same group, the same doses of raclopride were tested for their ability to reduce binge consumption of either fatty (shortening) or sucrose-containing (3.2, 10, and 32 %) foods after animals were given either daily or intermittent access to these foods ). Similar to the results of the study of Wong et al. (2009) , the 0.1 mg/kg dose of raclopride significantly increased intake of shortening among rats exposed to the limited-access protocol and given intermittent 1-h access to 100 % fat, but these effects were not observed among rats given daily access to fat ). The highest dose of raclopride (0.3 mg/kg) decreased sucrose consumption for all conditions of sucrose bingeing. In another study, rats treated with 0.3 mg/kg (IP) raclopride and given intermittent 4-h access to a 56 % solid fat emulsion or daily 4-h access to 18, 32, or 56 % solid fat emulsions significantly decreased their intake (Rao et al. 2008 ). Raclopride does not alter regular chow intake Rao et al. 2008; Wong et al. 2009 ), indicating that raclopride specifically influences consumption of palatable foods and only does so in animals that binge on these foods.
Relative to drug addiction, 0.1 mg/kg raclopride attenuates context-induced cocaine reinstatement (Crombag et al. 2002) and 0.25 mg/kg raclopride attenuates heroin-induced relapse (Shaham and Stewart 1996) . The administration of moderate (0.1 mg/kg) and high (0.3 mg/kg) doses of raclopride for five consecutive days prevents cannabinoid (WIN)-induced alcohol relapse (Alen et al. 2008) . Intra-amygdala infusion of raclopride produces a dose-dependent effect on cue-primed reinstatement of cocaine seeking that is akin to its effects on binge eating: a low dose stimulates reinstatement, while a higher dose attenuates it (Berglind et al. 2006) . Taken together, high doses of raclopride decrease, while low doses increase, fat and sucrose consumption in bingeing rats, but not in nonbingeing rats given daily access to palatable food. Relative to the reinstatement of drug seeking, raclopride's effects on sucrose bingeing are similar to those produced by intra-amygdala infusions but not systemic injections.
The D1 antagonist Sch 23390 reduces bingeing on palatable food. Treating rats with 0.1 or 0.3 mg/kg (IP) Sch 23390 reduces intake of 3.2, 10, and 32 % liquid sucrose solutions in rats given limited access (1 hour/ day) to sucrose either daily or intermittently, with effects more pronounced for rats given intermittent access . Furthermore, a dose of 0.3 mg/kg Sch 23390 significantly decreases shortening intake for rats given daily and intermittent 1-h access to fat, while a 0.3 mg/kg dose has no effect. Notably, Sch 23390 does not influence regular chow intake Rao et al. 2008; Wong et al. 2009 ). Similarly, treating rats with Sch 23390 significantly attenuates operant responding for access to cocaine-associated stimuli, but the response to standard chow-associated stimuli are not influenced at most doses (Weissenborn et al. 1996) . Sch 22390 also attenuates renewal of contextinduced cocaine self-administration (Crombag et al. 2002) , heroin-induced relapse (Shaham and Stewart 1996) , ethanol relapse (Liu and Weiss 2002) , and fooddeprived-induced heroin reinstatement (Tobin et al. 2009 ) in rats. Sch 22390 decreases nicotine self-administration (Sorge and Clarke 2009; Stairs et al. 2010 ) and cocaine self-administration (Sorge and Clarke 2009) . While Sch 22390 significantly attenuates cocaine seeking after a period of withdrawal in both males and females given shortaccess to cocaine self-administration, this effect is diminished in animals given extended access (Ramoa et al. 2013) , in line with the reduction in DA release, which occurs following extended access (discussed above). In summary, the D1 antagonist Sch 22390 inhibits consumption of palatable foods and attenuates the reinstatement of drug seeking.
Because enhanced DA release is observed in the NAc during bingeing, it is tempting to suggest that the effects of systemic D1 and D2 antagonism on bingeing are mediated by the NAc. Testing the ability of specific infusion of agonists and antagonists into the NAc to reduce bingeing is necessary. The D2 antagonist raclopride exerts a biphasic effect on binge consumption of palatable foods; this may arise as a consequence of the different nature of the two populations of D2 receptors (pre-and postsynaptic). Low doses of agonists preferentially stimulate presynaptic D2 autoreceptors, thereby diminishing DA release (Henry et al. 1998) . It can be hypothesized that low doses of the antagonist raclopride would also have a preferential effect on autoreceptors, thereby increasing DA efflux (e.g., See et al. 1991) and driving the consumption of palatable foods. A high dose would also block postsynaptic receptors, thereby decreasing consumption of palatable foods. These results indicate that DA release and binding to postsynaptic D1, and possibly D2, receptors stimulate binge eating. Increasing DA release through antagonism of D2 autoreceptors also increases bingeing. These results parallel findings of increased D1 binding and decreased D2 binding in the NAc in rats with a history of bingeing on palatable food. Taken together, it is likely that decreased NAc D2 expression leads to enhanced DA release during bingeing episodes while enhanced D1 expression primes postsynaptic neurons to respond more potently to DA released during a binge.
Transitioning to addiction: the neurobiology of regulated and compulsive behaviors
Once DA signaling in the mesolimbic circuitry causes drugseeking behavior to be "overlearned," the execution of habitual and automatic behavior involves the glutamatergic projection from the PFC to the NAc (for review, see Kalivas and O'Brien 2008; Koob and Le Moal 2001) . Hypofrontality further reduces the ability to regulate behaviors, thus playing a key role in the loss of control over drug seeking (for review, see Kalivas and O'Brien 2008) . This section reviews findings from animal and human binge eating studies that examine glutamatergic signaling and cortical activity.
Glutamatergic neurotransmission in BN
Alterations in the expression of glutamate receptors and receptor subunits have been extensively assessed following selfadministration of addictive drugs by rodents. Glutamate has multiple receptor types located both pre-and postsynaptically. Here, we discuss relevant data regarding three post-synaptic receptors that are known to mediate neuroplasticity: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), Nmethyl-D-aspartate (NMDA), and metabotropic glutamate receptor 5 (mGluR5).
Following abstinence from extended access cocaine selfadministration, there is an increase in NAc surface expression of the GluA1 subunit of the tetrameric AMPA receptor, but no change in the expression of the GluA2 subunit (Conrad et al. 2008 ). This adaptation results in increased expression of calcium-permeable, GluA2-lacking AMPA receptors (CP-AMPA), which in turn increases the excitability of postsynaptic neurons, thereby strengthening synaptic connections (Conrad et al. 2008) . Increased CP-AMPAs have been observed after 30, 45, and 70 days of withdrawal, but not after only 1 day of withdrawal (Conrad et al. 2008; Ferrario et al. 2011; Wolf and Tseng 2012) or after only short access to cocaine self administration (Purgianto et al. 2013) . Foodrestricted rats show a significant increase in postsynaptic density expression of GluA1 in the NAc relative to controls while GluA2 expression does not change (Peng et al. 2011) . Thus, it is feasible that the periods of food restriction that occur during BN cause the insertion of CP-AMPAs, which then alter the responsivity of post-synaptic neurons in the NAc to incoming glutamate. Self-administration of addictive drugs also results in an increase in synaptically released glutamate in the NAc, which drives relapse after a drug-free period; this increase has been shown to occur in the case of relapse to alcohol (Gass et al. 2011 ), cocaine (McFarland et al. 2003 , and heroin (LaLumiere and . The potentiated glutamate release combined with the highly excitable postsynaptic neurons containing CP-AMPAs results in a circuit that is primed to drive drug-seeking behavior (via the NAc projections to the motor output regions of the brain). To date, no studies utilizing animal models of BN or binge eating have examined glutamate levels in the NAc or other brain regions following consumption of palatable food after a period of abstinence (food restriction). However, if such an increase were to occur, it would support the hypothesis that the loss of control over consumption of palatable food and addictive drugs after a period of abstinence relies on a similar neurocircuitry.
Supporting the hypothesis that glutamate release is involved in BN, the NMDA receptor antagonist memantine decreases binge-like lard consumption in nondeprived rats and produces a concomitant increase in consumption of standard laboratory chow (Popik et al. 2011) . The same study showed that MTEP (3-(2-methyl-4-thiazolyl-ethynyl) pyridine), a negative allosteric modulator of mGluR5, resulted in a trend for reducing lard consumption. Using a baboon model of binge-eating disorder in which baboons were given intermittent access to sugar with ad libitum access to standard chow, Bisaga et al. (2008) found that both memantine and MTEP decrease binge-like consumption of sugar. A similar effect of memantine on the frequency of binge eating was observed in a clinical trial (Brennan et al. 2008) .
While glutamate microdialysis studies have yet to be conducted using animal models of BN, the fact that glutamate receptor antagonists memantine and MTEP decrease binge eating support the hypothesis that binge eating involves glutamatergic transmission, although potentially in a brain region outside the NAc. In rodents, MTEP has reliably been shown to decrease seeking of cocaine (Bäckström and Hyytiä 2006; Knackstedt et al. 2013; Kumaresan et al. 2009; Martin-Fardon et al. 2009 ), alcohol (Sidhpura et al. 2010) , methamphetamine (Osborne and Olive 2008) , and opioids (Brown et al. 2012) . Several small-scale clinical trials have found that memantine reduces the subjective effects of nicotine (Jackson et al. 2009 ) and heroin (Comer and Sullivan 2007) and reduces withdrawal symptoms from both alcohol (Krupitsky et al. 2007 ) and opioids (Bisaga et al. 2001 ). However, a larger, placebo-controlled study indicated that memantine does not reduce drinking in alcohol-dependent patients (Evans et al. 2007 ). Interestingly, in a 29-patient open label pilot study, memantine reduced time spent gambling and increased cognitive flexibility (Grant et al. 2010) , indicating that memantine may be effective in patients with addictions to behaviors such as gambling and binge eating but not to addictive drugs. In sum, although there is a paucity of research utilizing animal models of BN to examine alterations in glutamate transmission, preliminary findings reviewed in this section suggest that similar adaptations in the glutamate neurotransmitter system may underlie BN and drug seeking.
Loss of control
Drug addiction involves the transition from declarative, executive functions to habitual behaviors and a loss of control over drug taking, which results from a disruption of PFC activity (Kalivas and O'Brien 2008; Koob and Le Moal 2001) . As previously mentioned, one of the key characteristics of BN is a sense of loss of control overeating, with the inability to stop eating or control what or how much one is eating (American Psychiatric Association 2013). Functional magnetic resonance imaging studies have found that, relative to healthy controls, BN individuals exhibit significantly lower PFC activity during executive control cognitive tasks such as impulsivity control (Marsh et al. 2011; Marsh et al. 2009 ). Low levels of activity in the frontostriatal pathways, including the left inferolateral PFC, are related to impulsive responding (Marsh et al. 2009 ), indicating impaired executive functioning among BN-individuals. Relative to controls, BN individuals show higher activity in the PFC when they are presented with images of food (Uher et al. 2004 ), cued with negative words concerning body image (Miyake et al. 2010) , or shown overweight bodies (Spangler and Allen 2012) .
Taken together, BN individuals show hypofrontality when presented with nonfood-related cues and excessive activity when presented with disorder-related cues. This pattern of activity is also seen among drug addicts. Specifically, hypoactivity in the PFC in response to nondrug-related cognitive tasks is evident among chronic users of cocaine (Goldstein et al. 2007) , methamphetamine (Kim et al. 2011; Nestor et al. 2011; Salo et al. 2009 ), and alcohol (Crego et al. 2010; Maurage et al. 2012) . Presenting addicts with images of drug-related stimuli increases PFC activity among alcoholics (George et al. 2001; Grusser et al. 2004; Tapert et al. 2004) , cocaine (Wilcox et al. 2011) , and nicotie-dependent individuals (Lee et al. 2005) . Thus, BN individuals display aberrant patterns of PFC activity similar to drug addicted individuals.
The opioid system and binge eating
The opioid neuropeptide system mediates pleasure and analgesia, primarily through binding of opioid neuropeptides at the μ-opioid receptor (MOR). Many classes of addictive drugs release endogenous opioids or bind to opioid receptors, producing feelings of euphoria (for review, see (Goodman 2008; Koob and Le Moal 2001) . Rats that chronically selfadminister heroin show an increase in MOR binding in the NAc, hippocampus, VTA, and caudate putamen (Fattore et al. 2007) . Similarly, nonpurging BN rats cycled through the "sugar addiction" model exhibit a significant increase in MOR binding in the NAc shell, hippocampus, and cingulate cortex (Colantuoni et al. 2001) . Administering the opioid receptor antagonist naloxone to sugar-bingeing rats induces somatic signs of opiate dependency, such as teeth chattering, head shakes, and signs of anxiety (Colantuoni et al. 2002) . The same was not observed in rats that binged on a palatable diet composed of a sugar and fat combination , suggesting a specific neurobiological circuitry associated with sugar bingeing.
Naltrexone, an antagonist at μ-and kappa-opioid receptors, is used to treat addiction and shows promise for the treatment of BN (Conason and Sher 2006) . Naltrexone decreases bingeing of palatable foods among binge-eating rats Corwin and Wojnicki 2009; Giuliano et al. 2012; Wong et al. 2009 ). However, the ability of naltrexone to reduce consumption of palatable food after binge-like access varies with the composition of the palatable food, with high sucrose levels being more resistant to the suppressive effect Wong et al. 2009) . In human clinical studies of BN, naltrexone alone or in combination with the serotonin reuptake inhibitor fluoxetine decreases bulimic symptomology (e.g., Jonas and Gold 1986; Maremmani et al. 1996; Marrazzi et al. 1995; Mitchell et al. 1989) . Naltrexone is beneficial in the treatment of addiction to alcohol (Conason and Sher 2006) and heroin (Krupitsky et al. 2006) , but has been shown to be ineffective at reducing craving for other drugs (for review, see Modesto-Lowe and Van Kirk 2002) . A novel MOR antagonist, GSK1521498, has an affinity for this receptor that is three times higher than naltrexone. One study found that GSK1521498 reduced binge-like consumption of a chocolate diet and prevented the reduction in consumption of normal chow that often accompanies binge consumption of palatable food in rats (Giuliano et al. 2012) . Thus, the role of MOR in mediating binge eating and alcohol addiction appears to be similar.
Treatment implications
Applying addiction-focused treatment to BN may reduce the high rate of relapse associated with BN. However, removing addictive drugs from a drug addict's environment is plausible whereas food is necessary for life (Broft et al. 2011) . Furthermore, since BN individuals refrain from "taboo" foods during nonbingeing restriction periods (Fitzgibbon and Blackman 2000) , removing palatable foods from the environment of a BN individual may heighten guilt associated with ingestion of these foods, thus triggering inappropriate compensatory behaviors. Therefore, given similar neurobiological mechanisms underlying drug addiction and BN, pharmacotherapy used for drug addictions may reduce bingeing of palatable foods. Specifically, pharmaceutical treatment targeting DA, glutamate, or opioid neurotransmitter systems that are shown to be effective for drug addiction may similarly be beneficial for the treatment of BN. Cognitive behavioral therapy coupled with medication may be useful for transitioning habitual behaviors Increases with exposure to drug (Avena et al. 2006a (Avena et al. ,b, 2008a Decreases during fasting (Bahk et al. 2002) Decreases during withdrawal (Avena et al. 2006a (Avena et al. , 2008b Barak et al. 2011; Beckstead et al. 2004; Beitner-Johnson and Nestler 1991; Bello et al. 2002 Bello et al. , 2003 Ben-Shahar et al. 2006 Increases during re-exposure (Avena and Bocarsly 2012) Increases or no change during re-exposure depending on schedule of access (Bello et al. 2002 , Bello et al. 2003 Berggren et al. 2006; Berglind et al. 2006; Bernardini et al. 1991) D1 binding in NAc
Increases (Alen et al. 2008) Increases or no change depending on method of administration Bisaga et al. 2008 Bisaga et al. , 2001 Bocarsly et al. 2011; Bradberry and Roth 1989; Brennan et al. 2008; Brisman and Siegel 1984; Broft et al. 2011) D2 binding in NAc Decreases (Alen et al. 2008; Bromberg-Martin et al. 2010; Brown et al. 2012 ) Decreases for Coc, but increases for other drugs Bocarsly et al. 2011; Brennan et al. 2008; Bäckström and Hyytiä 2006) D3 mRNA in the NAc Increases (Brown et al. 2012) Increases Bisaga et al. 2001 Bisaga et al. , 2008 Bocarsly et al. 2011; Bradberry and Roth 1989; Brennan et al. 2008; Brisman and Siegel 1984) ΔFosB in NAc Increases (Carbaugh and Sias 2010; Casper et al. 2008) Increases (Cerruti et al. 1994; Colantuoni et al. 2001 Colantuoni et al. , 2002 Colby et al. 2003) DA in VTA Increases* (American Psychiatric 2013) Increases (Comer and Sullivan 2007; Conason and Sher 2006; Connor et al. 2008; Conrad et al. 2008 Conrad et al. , 2010 VTA DAT binding/mRNA Increases* (Corwin and Wojnicki 2006; Corwin and Wojnicki 2009) Increases for Amph and Nic, but not Coc (Cragg and Greenfield 1997; Crego et al. 2010; Crombag et al. 2002; Di Bella et al. 2000; Di Chiara and Imperato 1988) VTA TH Increases* Increases for Coc and Mor, but not Meth (Diana et al. 1998 (Diana et al. , 1999 Raclopride (IP) High doses decrease bingeing (DiLeone et al. 2012; El-Ghundi et al. 2007; Evans et al. 2007 ) High doses attenuate relapse (Fattore et al. 2007; Ferrari et al. 2002; Ferrario et al. 2011; Fitzgibbon and Blackman 2000) Low doses increase bingeing (DiLeone et al. 2012; El-Ghundi et al. 2007) Low doses stimulate reinstatement (Fitzgibbon and Blackman 2000) Sch 23390 (IP) Reduces sucrose and fat intake (El-Ghundi et al. 2007) Attenuates reinstatement (Fattore et al. 2007; Ferrari et al. 2002; Gaddnas et al. 2002; Gass et al. 2011; George et al. 2001 George et al. , 2011 German et al. 2012) GluA1 in the NAc Increases following restriction (Gervasini et al. 2012) Increases following 30-70 days abstinence (Giuliano et al. 2012; Goldstein et al. 2007; Goodman 2008; Grant et al. 2010) GluA2 in the NAc No changes following restriction (Gervasini et al. 2012) No changes following abstinence (Giuliano et al. 2012) Glutamate release in NAc Unknown* Increases (Grusser et al. 2004; Hagan and Moss 1991; Hagan and Moss 1997) Memantine Decreases bingeing (Hagan et al. 2002; Henry et al. 1998; Inoue et al. 1998) No effect (Jackson et al. 2009; Jonas and Gold 1986; Kalivas and Duffy 1991; Kalivas and O'Brien 2008; Kelz et al. 1999) MTEP Decreases bingeing (Hagan et al. 2002; Henry et al. 1998) Decreases drug seeking (Kim et al. 2011; Klein and Smith 2013; Knackstedt et al. 2013; Kohl et al. 1998; Koob and Le Moal 2001; Krupitsky et al. 2006 Krupitsky et al. , 2007 PFC activity Hypofrontality with nondisorder-related cues (Kumaresan et al. 2009; LaLumiere and Kalivas 2008 ) Hypofrontality with nondrug-related cues (Le Cozannet et al. 2013; Le Foll et al. 2003; Lee et al. 2005; Li et al. 2004; Lindblom et al. 2006; Liu and Weiss 2002) Hyperfrontality with disorder-related cues (Ljungberg et al. 1992; Lominac et al. 2012; Lu and Wolf 1997) Hyperfrontality with drug-related cues (Maremmani et al. 1996; Marrazzi et al. 1995; Marsh et al. 2011; Marsh et al. 2009; Martin-Fardon et al. 2009) back to declarative, regulated behaviors, thereby increasing sense of control over eating, reducing bingeing, and decreasing the usage of compensatory behaviors. At this time, the only Food and Drug Administration-approved medication for addiction that also shows promise for BN is naltrexone, although future studies that assess effects of naltrexone on bulimic symptomology are warranted (Ramoz et al. 2007) . Upon the development of additional pharmacotherapies targeting these neurotransmitter systems for the treatment of drug addiction, the shared neurobiological features of these disorders warrant testing such pharmacotherapies in animal models of BN.
Conclusions
This review synthesized results from human and animal studies of BN and drug addiction and found more similarities than differences in their underlying neurobiological mechanisms (see Table 1 ). Specifically, the results reviewed here indicate that the dopaminergic system, glutamatergic signaling, the opioid system, and cortical activity play similar roles in BN and drug addiction. These similarities are especially evident for sugar bingeing. A history of sugar bingeing and deprivation results in decreased DA levels in the NAc following fasting and enhanced release upon consumption of sweet food. Combined with an increase in postsynaptic D1 receptors, this enhanced DA release likely serves to sensitize animals to the rewarding effects of sweet food and/or the cues associated with consumption of such food, leading to an increase in the probability that animals will binge in the future. Preliminary evidence also indicates that glutamatergic adaptations in the NAc following a history of binge eating prime the postsynaptic neurons in this region to respond more strongly to cues associated with palatable food. These adaptations also occur in animals with a history of addictive drug self-administration. More research that examines VTA DA is necessary, but preliminary results highlight similarities between BN and addiction to some drugs. Differences between the two disorders include changes in NAc DA response following extended access to drug self-administration, NAc D2 binding, VTA DAT mRNA levels, and the efficacy of memantine to reduce symptoms. Although more empirical studies on the topic are necessary, the results presented here indicate that bingeing on palatable foods, mainly sugar, coupled with food restriction or purging influences neurobiology in a manner similar to that of addictive drugs. (Alen et al. 2008) Increases (Mateo et al. 2005) Naltrexone treatment Beneficial for bingeing of some foods* (DiLeone et al. 2012; El-Ghundi et al. 2007; Maurage et al. 2012; McFarland et al. 2003; McHugh et al. 2010; Metaxas et al. 2010; Mirenowicz and Schultz 1994; Mitchell et al. 1989; Miyake et al. 2010 ) Beneficial for Alc and Hern use, but not other drugs (Modesto-Lowe and Van Kirk 2002; Mukda et al. 2009; Nakagawa et al. 2011) DA dopamine, VTA ventral tegmental area, NAc nucleus accumbens, PFC prefrontal cortex, Amph amphetamine, Nic nicotine, Coc cocaine, Mor morphine, Meth methamphetamine, Alc alcohol, Hern heroin
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